Genentech gets two ROZLYTREK label updates; Roche's IMvigor011, forimtamig results stand
FDA approved labeling supplements for ROZLYTREK capsules and pellets, while Roche's prior-week bladder cancer and myeloma results and trial registrations carry forward.
The week's most notable move is a pair of FDA labeling approvals for Genentech's ROZLYTREK, alongside the previously reported Roche results postings and trial registrations that remain current.
- The FDA approved a labeling supplement for ROZLYTREK (entrectinib) 100mg and 200mg capsules under NDA212725, submission number 14, a labeling-class supplement with submission status "AP" dated 2026-10-01, sponsored by Genentech Inc.1
- A second ROZLYTREK labeling supplement was approved the same day for the 50mg/packet oral pellet formulation, under NDA218550, submission number 2, also a labeling supplement with approval status dated 2026-10-01, sponsored by Genentech Inc.2
- IMvigor011, a Phase III trial of atezolizumab versus placebo as adjuvant therapy in ctDNA-positive muscle-invasive bladder cancer after cystectomy, has posted results. The study is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive and are at high risk for recurrence following cystectomy3, with enrollment reaching 761 participants (actual)3 and Natera's Signatera assay used for ctDNA monitoring.
- A Phase Ib/II trial of forimtamig combinations in relapsed or refractory multiple myeloma has posted results. The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig4, with enrollment reaching 21 participants (actual)4.
- Genentech's Phase II trial of RO7965032 in geographic atrophy secondary to age-related macular degeneration remains registered and not yet recruiting, with an estimated enrollment of 321 participants5.
- Three Phase III petrelintide weight-management trials, ZUPREME-3, ZUPREME-4, and ZUPREME-5, remain registered as not yet recruiting, each with Zealand Pharma as a collaborator6, enrolling an estimated 3900, 600, and 2500 participants respectively across obesity/overweight populations with and without type 2 diabetes or cardiovascular disease.
- AMETRINE-SC, a Phase III trial of subcutaneous afimkibart induction therapy in moderately to severely active ulcerative colitis, remains registered as not yet recruiting, with Chugai Pharmaceutical and Pfizer listed as collaborators7 and an estimated enrollment of 350 participants7.
- Ametrine-2, the earlier Phase III afimkibart induction trial in ulcerative colitis, remains active not recruiting8 with an estimated enrollment of 350 participants8.
- The real-world observational study of polatuzumab vedotin (Polivy) in Chinese adults with diffuse large B-cell lymphoma remains active not recruiting, with an estimated enrollment of 1000 participants9.
- IMpower010, the Phase III atezolizumab trial in resected Stage IB-IIIA non-small cell lung cancer, remains completed, with enrollment of 1280 participants (actual)10.
- SONATA-MS, the observational study of subcutaneous ocrelizumab in relapsing-remitting multiple sclerosis, remains recruiting, with an estimated enrollment of 1800 participants11.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.